Anzeige
Mehr »
Donnerstag, 09.10.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EJMQ | ISIN: CH1276028821 | Ticker-Symbol: S3F0
Tradegate
09.10.25 | 09:31
11,120 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SANTHERA PHARMACEUTICALS HOLDING AG Chart 1 Jahr
5-Tage-Chart
SANTHERA PHARMACEUTICALS HOLDING AG 5-Tage-Chart
RealtimeGeldBriefZeit
11,12011,22009:59
11,12011,22009:59
GlobeNewswire (Europe)
193 Leser
Artikel bewerten:
(1)

Santhera Pharmaceuticals Holding AG: Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE (Vamorolone) in Russia

Pratteln, Switzerland, October 9, 2025 - Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Biomedica for the distribution of AGAMREE® (vamorolone) in Russia, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.

Under the terms of the agreement, Santhera will receive a percentage of net sales, in line with previous distribution agreements, with sales expected to begin in Q1 2026. This collaboration will enable access to AGAMREE for DMD patients across the country, facilitated through regional and national managed access programs. There are approximately 1,400 patients living with DMD in Russia [1].

Dario Eklund, Chief Executive Officer of Santhera, said: "This agreement will enable more children to access this important DMD treatment, and is the latest in a series of global agreements secured in 2025. We look forward to working closely with Biomedica in the months ahead."

Oleg Parosin, Founder and Chief Executive Officer of Biomedica added: "Our deep expertise in neurology and DMD, particularly with therapies that complement AGAMREE, combined with our track record of successful partnerships with leading EU and US companies, positions us as a strong and trusted partner for Santhera in Russia. We look forward to working together to accelerate access and ensure the availability of AGAMREE from early next year, enabling even more patients to benefit from this essential therapy."

About AGAMREE® (vamorolone)
AGAMREE is a novel drug with a mode of action based on binding to the same receptor as glucocorticoids but modifying its downstream activity. Moreover, it is not a substrate for the 11-ß-hydroxysteroid dehydrogenase (11ß-HSD) enzymes that may be responsible for local drug amplification and corticosteroid-associated toxicity in local tissues [2-5]. This mechanism has shown the potential to 'dissociate' efficacy from steroid safety concerns and therefore AGAMREE is positioned as a dissociative anti-inflammatory drug and an alternative to existing corticosteroids, the current standard of care in children and adolescent patients with DMD [2-5].

In the pivotal VISION-DMD study, AGAMREE met the primary endpoint Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks of treatment and showed a good safety and tolerability profile [2, 5]. The most commonly reported side effects were cushingoid features, vomiting, weight increase and irritability. Side effects were generally of mild to moderate severity.
Currently available data show that AGAMREE, unlike corticosteroids, has no restriction of growth [6] and no negative effects on bone metabolism as demonstrated by normal bone formation and bone resorption serum markers [7].

? This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

References:
[1] Gordey Foundation
[2] Dang UJ et al..
[3] Guglieri M et al.

[4] Liu X et al.
[7] Hasham et al., MDA 2022 Poster presentation. Link.

About Santhera
Santhera Pharmaceuticals.

AGAMREE® is a trademark of Santhera Pharmaceuticals.

About Biomedica
Biomedica is a pharmaceutical company specializing in the commercialization of rare disease, innovative, and breakthrough therapies in underserved and emerging markets. With a strong presence across Central and Eastern Europe (CEE), the Commonwealth of Independent States (CIS), Turkey, and Israel, Biomedica partners with leading biotechnology and pharmaceutical innovators to bring novel treatments to patients. Its key therapeutic areas include rare diseases, neurology, haematology, oncology, hepatology and ophthalmology. Leveraging its regional expertise and established market access capabilities, Biomedica is committed to ensuring the timely access and availability of innovative therapies for patients with high unmet medical needs.

For further information please contact:

Santhera
Catherine Isted, Chief Financial Officer:

IR@santhera.com

ICR Healthcare:

Santhera@icrhealthcare.com

Biomedica
Stan Filippin, Head of Business Development: bd@biomedica.bio

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

Attachment

  • 251009 Biomedica distirbution agreement_Final (https://ml-eu.globenewswire.com/Resource/Download/b056949e-7542-4eab-870c-c1357163b795)

© 2025 GlobeNewswire (Europe)
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.